Related Experiment Videos
Role of cell growth factor (interleukin-2) and its receptors in carcinoma cervix patients
1Anatomy Department, All India Institute of Medical Sciences, New Delhi.
Abstract:
Host immunity plays an important role in neoplasia. Neoplastic activity is known to correspond with the disturbances in immunological mechanisms. T-lymphocytes DNA replication and mitosis are determined by a critical threshold of signals generated by the interaction between interleukin-2 (IL-2) and its receptors. So we planned to study the level of IL-2 in carcinoma cervix patients. Twenty healthy (normal) and fifty carcinoma cervix patients were investigated. The level of IL-2 was estimated by thymidine incorporation [Anderson et al., Eur. J. Immun. 9 (1979) 581-587]. A remarkable decrease in concentration of IL-2 in serum of the patients (mean = 21.62 U/100 microliters) when compared with normal healthy individuals (36.86 U/100 microliters). Immunotherapy in the form of IL-2 can be suggested in such patients.
Insights
This study found lower levels of interleukin-2 (IL-2) in cervical cancer patients compared to healthy individuals. This suggests IL-2 immunotherapy could be a potential treatment for cervical cancer.
Area of Science:
- Immunology
- Oncology
- Biochemistry
Background:
- Host immunity is crucial in neoplasia, with immune disturbances linked to neoplastic activity.
- T-lymphocyte proliferation, essential for immune response, depends on interleukin-2 (IL-2) signaling.
- Cervical cancer involves complex immunological interactions that warrant further investigation.
Purpose of the Study:
- To investigate the serum levels of interleukin-2 (IL-2) in patients diagnosed with carcinoma cervix.
- To compare IL-2 concentrations between cervical cancer patients and healthy individuals.
- To explore the potential role of IL-2 in the pathogenesis of cervical cancer.
Main Methods:
- Serum samples were collected from 50 patients with carcinoma cervix and 20 healthy controls.
- Interleukin-2 (IL-2) levels were quantified using the thymidine incorporation assay.
- Statistical comparison was performed between the patient and control groups.
Main Results:
- Cervical cancer patients exhibited significantly lower serum levels of IL-2 (mean = 21.62 U/100 microliters) compared to healthy individuals (mean = 36.86 U/100 microliters).
- A marked decrease in IL-2 concentration was observed in the patient cohort.
- The findings indicate a potential deficiency in IL-2 signaling in the context of cervical cancer.
Conclusions:
- Reduced IL-2 levels in carcinoma cervix patients suggest a compromised immune response.
- Interleukin-2 (IL-2) may play a role in the immune surveillance against cervical cancer.
- Immunotherapy utilizing IL-2 could be a promising therapeutic strategy for cervical cancer patients.